Premier Biomedical (OTCQB:BIEI) announced it has terminated joint venture Premier Biomedical Pain Management Solutions.
As quoted in the press release:

Premier Biomedical has integrated the pain relief products business into a division of Premier, which will continue to develop and market an expanded array of natural and synthetic, 50-state legal CBD-based, generalized, neuropathic, and localized pain relief treatment products. Their products will continue to be sold through their website, www.painreliefmeds.com, as well as through an expanding network of distributors, pharmacies, healthcare professionals, and pain clinics.
Premier Biomedical earlier this week announced the introduction of topical skin patches with higher CBD content than previously. They also announced a higher CBD content topical roll-on to be introduced later this quarter.
William A. Hartman, President and CEO of Premier Biomedical, Inc. stated, “This restructuring allows us to access a wider array of resources to further our aggressive new product plans to better position us as a leader in the CBD-based pain relief products industry. The global pain relief market is currently in excess of $100 billion annually. We believe that our current and future products represent an effective alternative to opioid-based pain relief drugs without the associated health risks and addiction potential of narcotics.”


Click here to read the full press release.

Source: www.marketwired.com

As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.

A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.

Keep reading... Show less

The product will include polyphenols known to have significant health benefits.

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.

The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).

Keep reading... Show less

 Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) (“Canopy Growth” or “the Corporation”) announced today that EVP & CFO Mike Lee will be participating in a fireside chat at the BofA Securities Virtual Consumer & Retail Technology Conference on Thursday, March 11, 2021 at 9:30am ET .

Keep reading... Show less

Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”). The Company announces that further to its press release dated March 2, 2021, it has obtained TSX Venture Exchange approval to extend the closing date of its previously announced private placement of units (“Units”) until April 7, 2021. Each Unit is comprised of one (1) common share and one (1) warrant, exercisable for one common share at price of $0.11 per share, for a period of three (3) years from the date of Closing. The Company applied to extend the date of closing to allow a greater number of interested investors to participate.

For more information regarding the Company or the offering, please contact ir@hillstreetbevco.com, or

Keep reading... Show less